secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2026-06-23T11:00:41+00:00
Accession:  0001104659-26-076624
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis in-licenses ex-China rights to two clinical-stage compounds from Haisco for up to $1.46B
--------------------------------------------------------------------------------

- Upfront and near-term payments total up to $40M; potential milestones up to $1.421B plus tiered royalties.
- NXP100 (CFBi) has two MAAs under review in China for PNH; Ph3 ongoing in IgAN; Ph2 in LN.
- NXP200 (paradox-breaker BRAFi) showed >40% response in gliomas and durable responses in multiple tumors; Phase 1b ongoing.
- Deal transforms Nuvectis into late-stage clinical company with two best-in-class potential assets.
- Agreement subject to financing conditions to ensure sufficient capital for product development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926076624/0001104659-26-076624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926076624/tm2618439d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-076624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer